Do you want to refine your view?
B·R·A·H·M·S™ CgA II KRYPTOR™ as new opportunity in prostate cancer!
Thermo Scientific™ B·R·A·H·M·S™ CgA II KRYPTOR™ is the first and only fully automated immunofluorescent assay for determining CgA concentration in human serum and EDTA plasma. Thermo Scientific™ B·R·A·H·M·S™ CgA II KRYPTOR™ test is indicated as an aid to be used in conjunction with clinical evaluation for follow-up and monitoring of patients with neuroendocrine tumors (NETs) and for therapy monitoring of patients with prostate cancer. The test is further indicated as an aid to be used in conjunction with clinical evaluation for the diagnosis of patients with suspected pheochromocytomas.
Download the guide and learn how in prostate cancer patient management this test can aid with:
- Earlier identification of therapy resistance
- Better guidance for treatment regimens
- Higher confidence NEPC monitoring
- Ultimately helping improve patient management and support better outcomes
KRYPTOR is a trademark of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific.
2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. We hereby disclose that this email communication is for commercial purposes.